Arcturus Therapeutics Ltd (ARCT) Stock Price, Quote & News

Company Profile

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 900 2660

Website: arcturusrx.com

Address:

10628 Science Center Drive, Suite 250, San Diego, United States

bigchouse Nov. 28 at 4:13 AM

$ARCT Short interest as % of float 36.70%

0 · Reply

bigchouse Nov. 27 at 3:28 AM

$ARCT ARKG has 2,337,574 shares still. No change in the number of shares.

0 · Reply

wahoowa96 Nov. 26 at 8:38 PM

$ARCT Recode Therapeutics enters phase 2 on the inhaled mRNA CFTR ... RCT-2100 + ivacaftor of VRTX multiple ascending doses to figure out optimal dose and tolerability 12 patients six weeks per dose. I think Arcturus will be tight-lipped on the 15 mg results of ARCT-032 till at least going into 12 weeks study 1st half of 2026...so ARCT-810 OTCD is next news in the waiting. https://recodetx.com/recode-therapeutics-initiates-enrollment-of-phase-2-clinical-trial-of-rct2100-in-combination-with-ivacaftor-for-the-treatment-of-cystic-fibrosis/

1 · Reply

wahoowa96 Nov. 26 at 2:29 PM

$ARCT Almost there with third set of 6666 shares. Attacking 9-10's. Pain is temporary but quit is forever. -Lance Armstrong

1 · Reply

Newcar Nov. 26 at 11:03 AM

$ARCT 48%

0 · Reply

Iightning Nov. 26 at 5:28 AM

1ightning® Options Trade Alert (Actionable) | Buy $ARCT Dec 19 $8 Call | Enter: $0.25 Exit: $0.40 | Profit: 60.46% ROI | https://1ightning.com

0 · Reply

Dr_Feel_Good Nov. 26 at 3:08 AM

$ARCT greet vol today followed up with a nice bounce.. Back on my hit list this week before Thanksgiving. 🎯

0 · Reply

HedgeAlerts Nov. 26 at 2:39 AM

Hedge Alert Live - Protect Your Portfolio Contract: $ARCT $5.00 Put · DEC 19, 2025 Exp Entry Price: $0.05 - $0.25 Exit Price Target: $0.10 Profit Margin: +101% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

LiquidThetaOptions Nov. 26 at 12:46 AM

💎 LiquidTheta® Live Actionable Trade Asset: $ARCT Contracts: $ARCT June 18, 2026 $8 Calls Scale in: $1.50- $1.84 Scale out: $5.84-$10.02 Profit Potential : 292% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Sumdum_Phuq Nov. 25 at 10:19 PM

$ARCT Over 30% of the float is short as of Nov 14th. That's one heck of a lot of short shares. How about a surprise Joe to get the squeeze going?

0 · Reply

Arcturus Therapeutics to Attend Upcoming Investor Conference

Nov 10, 2025, 9:01 PM EST - 17 days ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 4:01 PM EST - 17 days ago

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

Nov 4, 2025, 4:01 PM EST - 23 days ago

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Oct 28, 2025, 4:01 PM EDT - 4 weeks ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025

Oct 22, 2025, 3:05 PM EDT - 5 weeks ago

Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture

Oct 22, 2025, 8:53 AM EDT - 5 weeks ago

Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results

Oct 22, 2025, 7:30 AM EDT - 5 weeks ago

Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program

Aug 11, 2025, 8:16 PM EDT - 3 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript

Aug 11, 2025, 4:01 PM EDT - 3 months ago

Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress

Jul 24, 2025, 4:01 PM EDT - 4 months ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Jun 30, 2025, 11:00 AM EDT - 5 months ago

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

Jun 23, 2025, 8:30 AM EDT - 5 months ago

Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency

May 12, 2025, 7:40 PM EDT - 7 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 7 months ago

Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

Apr 22, 2025, 4:01 PM EDT - 7 months ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

Apr 10, 2025, 8:00 AM EDT - 8 months ago

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Mar 6, 2025, 9:44 PM EST - 9 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:01 PM EST - 9 months ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

Mar 5, 2025, 4:30 PM EST - 9 months ago

Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Feb 24, 2025, 4:01 PM EST - 9 months ago

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

Feb 14, 2025, 8:30 AM EST - 10 months ago

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Feb 4, 2025, 8:30 AM EST - 10 months ago

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

Jan 31, 2025, 3:00 AM EST - 10 months ago

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

Jan 30, 2025, 4:01 PM EST - 10 months ago

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

Jan 10, 2025, 8:00 AM EST - 11 months ago

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

Jan 6, 2025, 4:01 PM EST - 11 months ago

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Dec 16, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 18, 2024, 8:00 PM EST - 1 year ago

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 1:44 PM EST - 1 year ago

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

Nov 14, 2024, 1:00 AM EST - 1 year ago

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Nov 11, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Nov 7, 2024, 11:24 PM EST - 1 year ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Sep 13, 2024, 8:15 AM EDT - 1 year ago

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Aug 27, 2024, 5:00 PM EDT - 1 year ago

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Aug 9, 2024, 5:27 AM EDT - 1 year ago

High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine

Aug 5, 2024, 8:50 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

Jul 18, 2024, 7:30 PM EDT - 1 year ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

Jul 1, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Jun 20, 2024, 8:00 AM EDT - 1 year ago

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Jun 8, 2024, 2:42 AM EDT - 1 year ago

Arcturus: A Hidden Gem In The Biotech Sector

Jun 7, 2024, 10:30 AM EDT - 1 year ago

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

May 28, 2024, 6:30 AM EDT - 1 year ago

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

bigchouse Nov. 28 at 4:13 AM

$ARCT Short interest as % of float 36.70%

0 · Reply

bigchouse Nov. 27 at 3:28 AM

$ARCT ARKG has 2,337,574 shares still. No change in the number of shares.

0 · Reply

wahoowa96 Nov. 26 at 8:38 PM

1 · Reply

wahoowa96 Nov. 26 at 2:29 PM

$ARCT Almost there with third set of 6666 shares. Attacking 9-10's. Pain is temporary but quit is forever. -Lance Armstrong

1 · Reply

Newcar Nov. 26 at 11:03 AM

$ARCT 48%

0 · Reply

Iightning Nov. 26 at 5:28 AM

1ightning® Options Trade Alert (Actionable) | Buy $ARCT Dec 19 $8 Call | Enter: $0.25 Exit: $0.40 | Profit: 60.46% ROI | https://1ightning.com

0 · Reply

Dr_Feel_Good Nov. 26 at 3:08 AM

$ARCT greet vol today followed up with a nice bounce.. Back on my hit list this week before Thanksgiving. 🎯

0 · Reply

HedgeAlerts Nov. 26 at 2:39 AM

0 · Reply

LiquidThetaOptions Nov. 26 at 12:46 AM

0 · Reply

Sumdum_Phuq Nov. 25 at 10:19 PM

$ARCT Over 30% of the float is short as of Nov 14th. That's one heck of a lot of short shares. How about a surprise Joe to get the squeeze going?

0 · Reply

Heloav8tr Nov. 25 at 8:33 PM

$ARCT added to my position and bought December 19th 7.50 calls for the short squeeze.

0 · Reply

bigchouse Nov. 25 at 5:48 PM

$ARCT Short squeeze soon?

0 · Reply

wahoowa96 Nov. 25 at 4:33 PM

$ARCT 6.66 here you are! Bought 66 shares to begin with

1 · Reply

Iightning Nov. 25 at 3:36 PM

1ightning® Options Trade Alert (Actionable) | Buy $ARCT Dec 19 $8 Call | Enter: $0.25 Exit: $0.40 | Profit: 60.46% ROI | https://1ightning.com

0 · Reply

AlexLevin Nov. 25 at 10:32 AM

$ARCT joinin the suit?

1 · Reply

Iightning Nov. 25 at 4:30 AM

1ightning® Options Trade Alert (Actionable) | Buy $ARCT Dec 19 $8 Call | Enter: $0.25 Exit: $0.40 | Profit: 60.46% ROI | https://1ightning.com

0 · Reply

HedgeAlerts Nov. 25 at 2:40 AM

Hedge Alert Live - Protect Your Portfolio Contract: $ARCT $5.00 Put · DEC 19, 2025 Exp Entry Price: $0.05 - $0.15 Exit Price Target: $0.10 Profit Margin: +102% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

bigchouse Nov. 25 at 1:06 AM

$ARCT Make that big announcement. SAN DIEGO--(BUSINESS WIRE)--Nov. 24, 2025-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that the Company will participate in the following investor conference: Piper Sandler 37th Annual Healthcare Conference (Fireside Chat) Tuesday, December 2, 2025 (12:30 p.m. ET)

0 · Reply

MoneyGroupLLC Nov. 24 at 6:09 PM

Enter: $ARCT Calls Strike Price: $8 Expiry Date: DEC 19 2025 Buy in Price: $0.38 - $0.40 Sell Price: $0.62 Profit : +63% (Turn every $1 into $1.63) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

NolAsrtormZ Nov. 24 at 3:14 PM

$GRI ... iPf is probably a good buy Considering $PLRX discontinued lost 900 million market cap $TVRD failed iPf lost 300 million market cap $ARCT lost 300 million market cap Gri trades at 6.7 million market cap You do the math

0 · Reply

bigchouse Nov. 24 at 2:48 PM

$ARCT Loaded on the morning dip.

0 · Reply

Newcar Nov. 24 at 2:47 PM

$ARCT wait $5 or buy now?

3 · Reply

Market Cap	193.21M
Revenue (ttm)	152.31M
Net Income (ttm)	-80.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-53.14%
Debt to Equity Ratio	0.00

Volume	715,500
Avg Vol	1,476,084
Day's Range	N/A - N/A
Shares Out	28.41M
Stochastic %K	53%
Beta	2.47
Analysts	Strong Sell
Price Target	$30.86